开发用于镰状细胞贫血儿童和成人持续性白蛋白尿的多基因风险评分
研究在镰状细胞贫血(SCA)患儿中识别APOL1、HMOX1、BCL11A和α-地中海贫血变异,构建三变异和四变异多基因风险评分(PRS),并在成人SCA队列中验证。两个队列中APOL1风险变异增加持续性白蛋白尿风险而α-地中海贫血具有保护作用,PRS-4与持续性白蛋白尿显著相关(SCCRIP p=0.004;UIC p=0.00016)。基于PRS分层,高风险和极高风险类别中分别有54%-89%发生持续性白蛋白尿。
要点
- 在SCCRIP儿童队列和UIC成人队列中,APOL1风险变异增加持续性白蛋白尿风险,α-地中海贫血具有保护作用。
- PRS-4与持续性白蛋白尿显著相关(SCCRIP p=0.004;UIC p=0.00016)。
- PRS-3高风险类别中58%(SCCRIP)和86%(UIC)发生持续性白蛋白尿,PRS-4极高风险类别中54%(SCCRIP)和89%(UIC)发生持续性白蛋白尿。
核心结论
- PRS可能识别持续性白蛋白尿高风险的SCA患者。
- 应用该PRS指导疾病修饰剂和肾脏保护治疗的早期实施可能有助于减轻SCA相关慢性肾脏病负担。
研究设计与样本
- 在SCCRIP纵向队列的SCA患儿中识别APOL1、HMOX1(rs743811)、BCL11A(rs1424407)和α-地中海贫血(α-3.7)变异。
- 分别检验各变异与持续性白蛋白尿的关联,检验三变异PRS(PRS-3:APOL1、BCL11A rs1424407和α-3.7),并在PRS-3基础上加入HMOX1(rs743811)构建四变异PRS(PRS-4),以高风险等位基因求和计算。
- 使用芝加哥伊利诺伊大学(UIC)成人SCA队列进行验证。
- 持续性白蛋白尿定义为3次连续测量中至少2次尿白蛋白与肌酐比值(UACR)≥30 mg/g。
- 试验注册号:NCT02098863。
主要发现
- 在两个队列中,APOL1风险变异增加持续性白蛋白尿风险,而α-地中海贫血具有保护作用。
- PRS-4与持续性白蛋白尿显著相关(SCCRIP p=0.004;UIC p=0.00016)。
- 按PRS分为三个风险类别时,PRS-3高风险类别中58%(SCCRIP队列)和86%(UIC队列)发生持续性白蛋白尿。
- 按PRS分为四个风险类别时,PRS-4极高风险类别中54%(SCCRIP队列)和89%(UIC队列)发生持续性白蛋白尿。
关键数值与推荐
- 持续性白蛋白尿定义:3次连续测量中至少2次UACR≥30 mg/g。
- PRS-3组成:APOL1、BCL11A(rs1424407)和α-3.7。
- PRS-4组成:在PRS-3基础上加入HMOX1(rs743811)。
- PRS计算采用高风险等位基因求和。
- PRS-4与持续性白蛋白尿关联:SCCRIP队列p=0.004,UIC队列p=0.00016。
临床怎么用
- 作者认为PRS可能识别持续性白蛋白尿高风险的SCA患者。
- 作者认为应用该PRS指导疾病修饰剂和肾脏保护治疗的早期实施可能有助于减轻SCA相关慢性肾脏病负担。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Albuminuria is associated with high-risk apolipoprotein-L1 variants (APOL1 G1/G2) in patients with sickle cell anemia (SCA). However, this gene variant does not account for all chronic kidney disease (CKD) risk. We hypothesized that we could develop a polygenic risk score (PRS) for CKD in SCA, combining APOL1 G1/G2 with other candidate genes that modify SCA severity and further stratify patients into risk categories based on this risk score. Variants in APOL1, HMOX1 (rs743811), BCL11A (rs1424407), and α-thalassemia (α -3.7) were identified in children with SCA enrolled in the Sickle Cell Clinical Research and Intervention Program longitudinal cohort (SCCRIP). We individually tested the association of these variants with persistent albuminuria, tested a three-variant PRS (PRS-3) (APOL1, BCL11A (rs1424407), and α-3.7), and developed a four-variant PRS (PRS-4) after adding HMOX1 (rs743811) to PRS-3 using the summation of high-risk alleles. An adult SCA cohort from the University of Illinois, Chicago (UIC), was used for validation. Persistent albuminuria was defined as having a urine albumin-to-creatinine ratio (UACR) ≥ 30 mg/g on at least 2 of 3 consecutive measurements. In both cohorts, APOL1 risk variants increased the risk while α-thalassemia protected against persistent albuminuria. PRS-4 was significantly associated with persistent albuminuria (SCCRIP: p = 0.004; UIC: p = 0.00016). When stratifying patients into three and four risk categories based on the PRS, 58% and 86% of the high-risk (PRS-3) and 54% and 89% of very high-risk (PRS-4) categories developed persistent albuminuria cases in the SCCRIP and UIC cohorts, respectively. A PRS may identify high-risk SCA patients for albuminuria. Applying this PRS to guide the early implementation of disease modifiers and renoprotective therapies may help reduce the burden of SCA-related CKD. Trial Registration: NCT02098863.
引用
- Zahr RS, Kang G, Zhang X, et al. Development of Polygenic Risk Score for Persistent Albuminuria in Children and Adults With Sickle Cell Anemia. Am J Hematol. 2025. PMID: 40186439. doi:10.1002/ajh.27678
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。